Home | Business News | Browse by Publication | P | PR Newswire

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts.

Article Excerpt
AURORA, Ontario, Nov. 5 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.

The double-blind and placebo-controlled Phase II trial is underway at multiple centers in Germany and Sweden. Patients participating in the trial self-administer active treatment or control cream to the external ano-genital region twice-daily, for five consecutive days per week over a treatment period of eight weeks, with a follow-up visit at 16 weeks. Only female subjects were enrolled in the trial in order to avoid inter-sex treatment variations. The trial was designed to enroll 120 patients, whereby half were intended to receive Topical Interferon Alpha-2b and the other half a vehicle cream intended to serve as a placebo control. The primary endpoint for the trial will be comparison of the proportion of patients with complete clearance of their baseline lesions during the eight week treatment period.

"This is an important milestone for Helix's Topical Interferon Alpha-2b clinical program," said John Docherty, president and COO of Helix BioPharma. "Our efforts to enhance the recruitment rate over recent months have been successful, and we...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!